Peripheral Artery Disease: What Blood Tests Can Tell You

Peripheral artery disease, or PAD, often involves narrowing of the arteries that supply the legs. Blood tests can identify important risk factors and help track treatment. They cannot reliably tell you whether blood flow to your legs is restricted. That takes a different kind of assessment, such as an ankle-brachial index and, when needed, ultrasound.

Artery plaque and the causes of leg pain

Atherosclerotic plaque can narrow an artery and reduce the oxygen reaching the muscles. One possible sign is pain when walking that eases with rest. Not everyone with PAD follows that pattern: some people have different symptoms, while others initially have none.

PAD also says something about the health of your other blood vessels. People with atherosclerosis in their leg arteries often face a higher risk of heart attack and stroke. The NHLBI explains the connection. Recognizing PAD and treating it appropriately can help reduce symptoms and the risk of complications.

Blood tests cover different parts of that risk. LDL cholesterol, ApoB and lipoprotein(a) concern particles that contribute to atherosclerosis. HbA1c helps assess glucose regulation, and kidney tests add further context. Inflammation and clotting markers, including hs-CRP, interleukin-6, fibrinogen and D-dimer, are studied or used for particular clinical questions. Together, they do not constitute a general blood screen that reliably detects silent blockages in leg arteries.

Sudden severe leg pain with a cold, pale or numb leg can signal an acute loss of blood flow. Seek emergency medical help immediately; do not wait for laboratory results.

Why cholesterol and other lipid results matter in PAD

Confirmed atherosclerotic PAD calls for attention to the whole cardiovascular picture: smoking, blood pressure, diabetes and blood lipids. LDL cholesterol is an established treatment measure. ApoB can add information about the concentration of atherogenic particles.

Older summaries may mention LDL below 100 or around 70 mg/dL and ApoB below roughly 80 mg/dL. Those are not universal targets for someone with PAD. The 2024 US PAD guideline recommends high-intensity statin treatment aiming for at least a 50% LDL reduction. The 2026 US dyslipidemia guideline specifies LDL below 55 mg/dL for very-high-risk atherosclerotic cardiovascular disease and below 70 mg/dL for the other established-disease risk category. The ACC discussion of both guidelines explains the distinction. Your medical history determines which category and treatment apply.

Lipoprotein(a), or Lp(a), is largely inherited. Commonly used risk thresholds are 50 mg/dL or 125 nmol/L. These are not exact equivalents that can be converted for every person. Because particle sizes vary, mass in mg/dL and particle concentration in nmol/L have no single universal conversion factor. The 2022 EAS consensus explains how to interpret the result.

Hs-CRP can indicate inflammation, but it does not specifically identify an unstable plaque in the leg. Its familiar categories of below 1, 1–3 and above 3 mg/L are not PAD severity grades. The atherogenic index of plasma, or AIP, is the base-10 logarithm of triglycerides divided by HDL cholesterol, both measured in mmol/L. It is an additional research marker; cutoffs such as below 0.11 or above 0.21 are not established PAD treatment targets.

What blood tests leave unanswered

Good laboratory results do not prove that an artery is open or that blood flow is adequate. An existing narrowing can still cause symptoms even when cholesterol treatment is working. Conversely, a high LDL result does not tell you where an artery is narrowed.

Diagnosis involves assessing symptoms, pulses and blood flow. The ankle-brachial index compares blood pressure at the ankle and arm; other vascular tests may follow when needed. These answer different questions from a lipid panel. Blood tests complement the assessment by identifying treatable risk factors and helping monitor treatment safety.

Depending on the situation, care can include medication, stopping smoking, an appropriate walking program, wound care and sometimes a vascular procedure. Wounds that do not heal, pain at rest or new changes in a foot need prompt assessment. Waiting for an inflammation or cholesterol number to fall is not enough.

Frequently asked questions

What are blood tests for PAD?

They are tests for risk factors and related conditions, such as a lipid panel, glucose measures and kidney function. They complement vascular examinations. A particular commercial biomarker panel cannot diagnose PAD on its own or reliably rule it out.

Why are these tests useful?

They can identify risks that treatment can change, help set goals and monitor whether a treatment is working safely. Confirmed PAD calls for comprehensive cardiovascular prevention because other arteries may also be affected.

Can I have blood collected at home?

In some areas, a trained professional can collect a venous sample at home. The sample needs appropriate transport, and someone should be responsible for discussing the results with you. If you have new leg pain, a cold foot or wounds that are not healing, home collection does not replace a direct examination.

How often should results be checked?

The schedule depends on your diagnosis, risk and treatment. After a change in lipid treatment, another test within several weeks may be useful, with longer intervals later. Because Lp(a) is largely inherited, it usually does not need frequent repeat testing. An automatic annual panel of everything is no substitute for an individual plan.

What can affect the results?

Genetics, medicines, and thyroid, liver or kidney conditions can alter lipid results. Infections affect hs-CRP, while meals and alcohol can change triglycerides. Pregnancy and other special circumstances also matter. Remember that LDL cholesterol measures the amount of cholesterol carried, not the total number of atherogenic particles directly.

How should I prepare for the blood draw?

Your practice or laboratory will tell you whether to fast. ApoB and Lp(a) alone usually do not require fasting, although a particular triglyceride or AIP protocol may call for eight to twelve hours without food. Take medicines according to the plan agreed with your clinician. Do not delay care for acute symptoms while waiting for ideal testing conditions.

Can changes in daily life help?

Yes. Stopping smoking, appropriate physical activity and diet are important parts of care. A structured walking program can help people with symptomatic PAD, but it needs to suit the clinical situation. These steps usually change Lp(a) very little; their benefits for overall risk still matter. One unchanged number does not erase the value of a healthier routine.

How are the results interpreted?

Alongside the diagnosis, symptoms and treatment goals. Lower LDL or ApoB during appropriate treatment can be encouraging, but it does not directly show that a narrowing has disappeared. Neither hs-CRP nor AIP measures current blood flow to the legs. A useful results discussion explains which findings call for action and which provide additional context.

Sources and context

These sources address vascular disease, lipoproteins and supporting laboratory measures. The LDL discussion incorporates the 2024 and 2026 US guidelines. A laboratory result on its own cannot replace an assessment of blood flow to the legs.

References:

Criqui MH, Aboyans V (2015). Epidemiology of peripheral artery disease. Circulation Research, 116(9), 1509-1526. https://doi.org/10.1161/CIRCRESAHA.116.303849 Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, … Catapano AL (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925-3946. https://doi.org/10.1093/eurheartj/ehac361 Ridker PM (2003). Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107(3), 363-369. https://doi.org/10.1161/01.CIR.0000053730.47739.3C Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK (2016). Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights, 11, 95-104. https://doi.org/10.4137/BMI.S38440 National Heart, Lung, and Blood Institute. (n.d.). Peripheral artery disease. https://www.nhlbi.nih.gov/health/peripheral-artery-disease

American College of Cardiology (2026). Implications of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline for Lipid Management in Vascular Disease. https://www.acc.org/latest-in-cardiology/articles/2026/06/15/14/16/implications-of-the-2026-multisociety-dyslipidemia-guideline